Researchers find important biomarker in Iressa research

Cancer researchers at Cedars-Sinai say they've found an important biomarker among the small group of patients that respond to gefitinib, or Iressa. A protein called EMP-1 is present among the patients who don't respond. Researchers have been working on finding out why a group of patients respond to Iressa while others receive no benefit. These molecular clues are considered key to determining better who would benefit from the treatment.

- read this article from Medical News Today for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.